This site is intended for healthcare professionals

Molnupiravir, an investigational oral antiviral COVID-19 treatment, receives Special Approval for Emergency in Japan.- Merck Inc., + Ridgeback Biotherapeutics.

Read time: 1 mins
Published:25th Dec 2021
Merck Inc., and Ridgeback Biotherapeutics announced that Japan’s Ministry of Health, Labor and Welfare has granted Special Approval for Emergency in Japan for molnupiravir, an investigational oral antiviral medicine, for infectious disease caused by SARS-CoV-2.

Special Approval for Emergency is the process under Article 14-3 of the Pharmaceuticals and Medical Devices Act to approve a medical product swiftly in an emergency situation to protect public health. Under a previously announced supply agreement, the Japanese government will purchase 1.6 million courses of molnupiravir to accelerate access to patients.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.